International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response

Summary

The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing progression to critical illness, multiorgan failure, or death. Our objective is to determine whether modulating the host tissue response improves clinical outcomes among patients with COVID-19.

Timeline

Start

2022-10-27

Primary completion

2023-12-14

Completion

2023-12-14

Outcome

Outcome not reported

Stopped: “Following a meeting of the DSMB on 20th September 2023, the recommendation was made to the sponsor on 26th September 2023 that the Fostamatinib arm of the trial ceases enrolment and study medication is discontinued immediately.”

Drugs

Indications